Last reviewed · How we verify
Dermatop (PREDNICARBATE)
Dermatop (PREDNICARBATE) is a corticosteroid medication that targets the glucocorticoid receptor. It is a small molecule that has been used to treat various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. Originally developed by Valeant Pharms North, it is now owned by Valeant Bermuda and is off-patent. Dermatop is approved for use in the treatment of several skin conditions and has been available since 1991. As an off-patent medication, it is available from generic manufacturers.
At a glance
| Generic name | PREDNICARBATE |
|---|---|
| Sponsor | Bausch Health |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
- Atopic dermatitis
- Contact dermatitis
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Lichen simplex chronicus
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Scalp psoriasis
- Seborrheic dermatitis
Common side effects
- Local reactions (erythema, swelling, pruritus, tenderness, pain at injection site)
- Local reactions (erythema, swelling, pruritus, tenderness, pain at injection site)
- Systemic reactions (generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, hypotension, shock)
- Systemic reactions in rush immunotherapy
- Systemic reactions in conventional immunotherapy
Serious adverse events
- Shock
- Laryngeal edema
- Angioedema
- Fatal systemic reactions
Key clinical trials
- 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat (PHASE1)
- Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dermatop CI brief — competitive landscape report
- Dermatop updates RSS · CI watch RSS
- Bausch Health portfolio CI